CytomX Therapeutics Inc <CTMX.OQ> expected to post a loss of 8 cents a share - Earnings Preview
CytomX Therapeutics Inc CTMX.OQ CTMX.O is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The South San Francisco California-based company is expected to report a 41.2% decrease in revenue to $14.78 million from $25.12 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for CytomX Therapeutics Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for CytomX Therapeutics Inc is $5.50, about 56.5% above its last closing price of $2.39
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 0.12 | 0.12 | 0.27 | Beat | 117.7 |
Dec. 31 2025 | -0.15 | -0.20 | 0.23 | Beat | 217.5 |
Sep. 30 2024 | -0.16 | -0.17 | 0.07 | Beat | 140.7 |
Jun. 30 2024 | -0.12 | -0.14 | -0.08 | Beat | 44.2 |
Mar. 31 2024 | -0.08 | -0.08 | 0.17 | Beat | 305.2 |
Dec. 31 2023 | 0.01 | -0.03 | 0.01 | Beat | 135 |
Sep. 30 2023 | -0.15 | -0.19 | 0.04 | Beat | 121.2 |
Jun. 30 2023 | -0.18 | -0.20 | -0.02 | Beat | 90.2 |
This summary was machine generated August 5 at 22:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
